Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Pipeline Review, H2 2017
SUMMARY
According to the recently published report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017'; Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Estrogen-related receptor alpha (ERR?) or Steroid hormone receptor ERR1 is a nuclear receptor that is encoded by the estrogen related receptor alpha (ESRRA) gene. ERR? regulates genes involved in mitochondrial biogenesis, gluconeogenesis, and fatty acid metabolism. ERR? acts as a transcriptional activator of CYP11B1 and CYP11B2 which indicates that this nuclear receptor may be required for the production of cortisol and aldosterone in the adrenal gland.
The report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017' outlays comprehensive information on the Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Oncology which include indications Breast Cancer, Obesity, Type 2 Diabetes and Multiple Myeloma (Kahler Disease).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017'; Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Estrogen-related receptor alpha (ERR?) or Steroid hormone receptor ERR1 is a nuclear receptor that is encoded by the estrogen related receptor alpha (ESRRA) gene. ERR? regulates genes involved in mitochondrial biogenesis, gluconeogenesis, and fatty acid metabolism. ERR? acts as a transcriptional activator of CYP11B1 and CYP11B2 which indicates that this nuclear receptor may be required for the production of cortisol and aldosterone in the adrenal gland.
The report 'Steroid Hormone Receptor ERR1 - Pipeline Review, H2 2017' outlays comprehensive information on the Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders and Oncology which include indications Breast Cancer, Obesity, Type 2 Diabetes and Multiple Myeloma (Kahler Disease).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA)
- The report reviews Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Overview
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Companies Involved in Therapeutics Development
Lead Pharma Holding BV
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Drug Profiles
CAS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAS-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Estrogen Related Receptor Alpha for Metabolic Disorders and Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESRRA for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Overview
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Companies Involved in Therapeutics Development
Lead Pharma Holding BV
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Drug Profiles
CAS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAS-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Estrogen Related Receptor Alpha for Metabolic Disorders and Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ESRRA for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16388 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Steroid Hormone Receptor ERR1 (Estrogen Receptor Like 1 or Estrogen Related Receptor Alpha or Nuclear Receptor Subfamily 3 Group B Member 1 or NR3B1 or ESRRA) - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Lead Pharma Holding BV, H2 2017
Dormant Projects, H2 2017
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indication, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Lead Pharma Holding BV, H2 2017
Dormant Projects, H2 2017
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
Lead Pharma Holding BV
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
COMPANIES MENTIONED
Lead Pharma Holding BV
